Vaccine Development
- PMID: 38754940
- DOI: 10.1016/j.pcl.2024.01.018
Vaccine Development
Abstract
This article considers ethical considerations surrounding pediatric vaccine development for pandemic preparedness, examines some historical cases of pediatric vaccines developed during past smallpox, influenza, and 2019 coronavirus disease pandemics, and discusses the current state of vaccine development for pandemic preparedness, including vaccines against smallpox/mpox, influenza, anthrax, and Ebola that are included in the US Strategic National Stockpile and vaccines being developed against priority pathogens identified by the World Health Organization.
Keywords: Anthrax; COVID-19; Ebola; Emerging infections; Influenza; Mpox; Pediatric vaccines; Smallpox.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures E.A. Hammershaimb and J.D. Campbell are investigators on clinical trials of COVID-19 vaccines developed by Moderna and Novavax and of an anthrax vaccine developed by Emergent. Their institution receives funds for the conduct of these trials; the authors have no direct financial interests in any of these companies.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
